Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier

Journal of Neuroscience Research

Volumn 95, Issue 7, 2017, Pages 1513-1522

  Biemans, Elisanne A L M ^a   Jäkel, Lieke ^a   de Waal, Robert M W ^a   Kuiperij, H Bea ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

amyloid ; blood brain barrier; clearance; hCMEC D3; in vitro model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ARTICLE; BLOOD BRAIN BARRIER; CELL CULTURE; CLEARANCE; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; MODEL; PRIORITY JOURNAL; PROTEIN TRANSPORT; TIGHT JUNCTION; BRAIN; CELL LINE; CYTOLOGY; METABOLISM;

AMYLOID BETA-PEPTIDES; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; HUMANS; PEPTIDE FRAGMENTS; TIGHT JUNCTIONS;

EID: 84991106681     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23964     Document Type: Article

References (41)

1. Alabanza LM, Bynoe MS. 2012. Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. J Neuroimmunol 245(1-2):48–55.
2. Andras IE, Eum SY, Huang W, Zhong Y, Hennig B, Toborek M. 2010. HIV-1-induced amyloid beta accumulation in brain endothelial cells is attenuated by simvastatin. Mol Cell Neurosci 43(2):232–243.
3. Andras IE, Rha G, Huang W, Eum S, Couraud PO, Romero IA, Hennig B, Toborek M. 2008. Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells. Mol Pharmacol 73(5):1424–1433.
4. Bali J, Gheinani AH, Zurbriggen S, Rajendran L. 2012. Role of genes linked to sporadic Alzheimer's disease risk in the production of beta-amyloid peptides. Proc Natl Acad Sci U S A 109(38):15307–15311.
5. Boyer-Di Ponio J, El-Ayoubi F, Glacial F, Ganeshamoorthy K, Driancourt C, Godet M, Perriere N, Guillevic O, Couraud PO, Uzan G. 2014. Instruction of circulating endothelial progenitors in vitro towards specialized blood-brain barrier and arterial phenotypes. PLoS One 9(1):e84179.
6. Bruinsma IB, Wilhelmus MM, Kox M, Veerhuis R, de Waal RM, Verbeek MM. 2010. Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta(1-40)-mediated cell death. Brain Res 1315:169–180.
7. Candela P, Gosselet F, Saint-Pol J, Sevin E, Boucau MC, Boulanger E, Cecchelli R, Fenart L. 2010. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 22(3):849–859.
8. Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE. 2011. Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15(5):1167–1178.
9. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115(11):3285–3290.
10. Cucullo L, Couraud PO, Weksler B, Romero IA, Hossain M, Rapp E, Janigro D. 2008. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab 28(2):312–328.
11. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7):907–913.
12. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43(3):333–344.
13. Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M. 2013. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood–brain barrier model for drug permeability studies. Fluids Barriers CNS 10:33–33.
14. Elali A, Rivest S. 2013. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Front Physiol 4:45.
15. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. 2008. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 586(7):1937–1949.
16. Hsuchou H, Kastin AJ, Tu H, Joan Abbott N, Couraud PO, Pan W. 2010. Role of astrocytic leptin receptor subtypes on leptin permeation across hCMEC/D3 human brain endothelial cells. J Neurochem 115(5):1288–1298.
17. Kumar-Singh S. 2008. Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav 7 Suppl 1:67–82.
18. LaFerla FM, Oddo S. 2005. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11(4):170–176.
19. Liu W, Wang P, Shang C, Chen L, Cai H, Ma J, Yao Y, Shang X, Xue Y. 2014. Endophilin-1 regulates blood–brain barrier permeability by controlling ZO-1 and occludin expression via the EGFR–ERK1/2 pathway. Brain Res 1573:17–26.
20. Lopez-Ramirez MA, Fischer R, Torres-Badillo CC, Davies HA, Logan K, Pfizenmaier K, Male DK, Sharrack B, Romero IA. 2012. Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells. The Journal of Immunology 189(6):3130–3139.
21. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. 2012. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9(1):23.
22. Markoutsa E, Pampalakis G, Niarakis A, Romero IA, Weksler B, Couraud PO, Antimisiaris SG. 2011. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm 77(2):265–274.
23. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. 2010. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012):1774.
24. Merino-Zamorano C, Fernandez-de Retana S, Montanola A, Batlle A, Saint-Pol J, Mysiorek C, Gosselet F, Montaner J, Hernandez-Guillamon M. 2016. Modulation of Amyloid-beta1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier. J Alzheimers Dis 53(2):677–691.
25. Miners JS, Barua N, Kehoe PG, Gill S, Love S. 2011. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70(11):944–959.
26. Poller B, Gutmann H, Krahenbuhl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J. 2008. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem 107(5):1358–1368.
27. Qosa H, LeVine H, 3rd, Keller JN, Kaddoumi A. 2014. Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842(9):1806–1815.
28. Rensink AA, de Waal RM, Kremer B, Verbeek MM. 2003. Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 43(2):207–223.
29. Sagare AP, Bell RD, Zlokovic BV. 2012. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2(10).
30. Sajja R, Prasad S, Cucullo L. 2014. Impact of altered glycaemia on blood-brain barrier endothelium: an in vitro study using the hCMEC/D3 cell line. Fluids Barriers CNS 11(1):8.
31. Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron 6(4):487–498.
32. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA. 2010. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14(5):1101–1112.
33. Tai LM, Loughlin AJ, Male DK, Romero IA. 2009. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 29(6):1079–1083.
34. Timmer NM, Kuiperij HB, de Waal RM, Verbeek MM. 2010a. Do amyloid beta-associated factors co-deposit with Abeta in mouse models for Alzheimer's disease? J Alzheimers Dis 22(2):345–355.
35. Timmer NM, Schirris TJ, Bruinsma IB, Otte-Holler I, van Kuppevelt TH, de Waal RM, Verbeek MM. 2010b. Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Abeta40 (DAbeta(1-40)) are modulated by sulfate moieties of heparin. Neurosci Res 66(4):380–389.
36. Urich E, Lazic SE, Molnos J, Wells I, Freskgard PO. 2012. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 7(5):e38149.
37. Weksler B, Romero IA, Couraud PO. 2013. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10(1):16.
38. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19(13):1872–1874.
39. Wilhelmus MM, Otte-Holler I, van Triel JJ, Veerhuis R, Maat-Schieman ML, Bu G, de Waal RM, Verbeek MM. 2007. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 171(6):1989–1999.
40. Zlokovic BV. 2011. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12):723–738.
41. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. 1996. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93(9):4229–4234.